Clinical course in Parkinson's disease with elevated homocysteine

Padraig E. O'Suilleabhain; Robert Oberle; Cristina Bartis; Richard B. Dewey; Teodoro Bottiglieri; Ramon Diaz-Arrastia

doi:10.1016/j.parkreldis.2005.10.002

Clinical course in Parkinson's disease with elevated homocysteine

Padraig E. O'Suilleabhain, Robert Oberle, Cristina Bartis, Richard B. Dewey, Teodoro Bottiglieri, Ramon Diaz-Arrastia

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 μmol/L, n=31) at baseline were compared with the rest (n=66). Overall progression in 2 years did not significantly differ (p=0.20). Four subjects with elevated and one with normal Hcy had died (p=0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.

Original language	English (US)
Pages (from-to)	103-107
Number of pages	5
Journal	Parkinsonism and Related Disorders
Volume	12
Issue number	2
DOIs	https://doi.org/10.1016/j.parkreldis.2005.10.002
State	Published - Mar 2006

Keywords

Cognition
Homocysteine
Parkinson's disease
Vitamins

ASJC Scopus subject areas

Neurology
Geriatrics and Gerontology
Clinical Neurology

Access to Document

10.1016/j.parkreldis.2005.10.002

Cite this

@article{76566f2770594462a3d989be63be1683,

title = "Clinical course in Parkinson's disease with elevated homocysteine",

abstract = "Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 μmol/L, n=31) at baseline were compared with the rest (n=66). Overall progression in 2 years did not significantly differ (p=0.20). Four subjects with elevated and one with normal Hcy had died (p=0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.",

keywords = "Cognition, Homocysteine, Parkinson's disease, Vitamins",

author = "O'Suilleabhain, {Padraig E.} and Robert Oberle and Cristina Bartis and Dewey, {Richard B.} and Teodoro Bottiglieri and Ramon Diaz-Arrastia",

year = "2006",

month = mar,

doi = "10.1016/j.parkreldis.2005.10.002",

language = "English (US)",

volume = "12",

pages = "103--107",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Clinical course in Parkinson's disease with elevated homocysteine

AU - O'Suilleabhain, Padraig E.

AU - Oberle, Robert

AU - Bartis, Cristina

AU - Dewey, Richard B.

AU - Bottiglieri, Teodoro

AU - Diaz-Arrastia, Ramon

PY - 2006/3

Y1 - 2006/3

N2 - Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 μmol/L, n=31) at baseline were compared with the rest (n=66). Overall progression in 2 years did not significantly differ (p=0.20). Four subjects with elevated and one with normal Hcy had died (p=0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.

AB - Elevated homocysteine (Hcy), prevalent in Parkinson's disease (PD), is potentially a modifiable risk factor for neurologic deterioration. We measured cognitive, affective and motor changes over 2 years in a cohort of people with early PD. Subjects whose Hcy had been elevated (>14 μmol/L, n=31) at baseline were compared with the rest (n=66). Overall progression in 2 years did not significantly differ (p=0.20). Four subjects with elevated and one with normal Hcy had died (p=0.03). We conclude that hyperhomocysteinemia does not predict significantly worse progression over 2 years in early PD. The data raised the possibility of higher mortality, but the number of deaths was small.

KW - Cognition

KW - Homocysteine

KW - Parkinson's disease

KW - Vitamins

UR - http://www.scopus.com/inward/record.url?scp=32544451137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544451137&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2005.10.002

DO - 10.1016/j.parkreldis.2005.10.002

M3 - Article

C2 - 16368256

AN - SCOPUS:32544451137

SN - 1353-8020

VL - 12

SP - 103

EP - 107

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

IS - 2

ER -

Clinical course in Parkinson's disease with elevated homocysteine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this